McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is quoted in a September 29, 2017 edition of BioWorld in an article entitled, ” Amgen-Abbvie agreement erases uncertainty for Humira biosimilar.” In a win-win for both companies, Amgen Inc. and Abbvie Inc. reached a settlement that includes definitive launch dates for Amgen’s biosimilar to Humira (adalimumab) in the EU and U.S. View the article